Cargando…

An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes

INTRODUCTION: Understanding antibiotic resistance and toxin profiles among staphylococcal isolates in ocular infections can aid in therapeutic management and infection prevention strategies. We evaluated in vitro antibiotic resistance patterns and molecular traits of staphylococci isolated from pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schechter, Barry A., Sheppard, John D., Sanfilippo, Christine M., DeCory, Heleen H., Asbell, Penny A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054570/ https://www.ncbi.nlm.nih.gov/pubmed/31732871 http://dx.doi.org/10.1007/s40123-019-00223-y

Ejemplares similares

Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study
por: Alter, Sherman J., et al.
Publicado: (2019)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
por: Blondeau, Joseph, et al.
Publicado: (2021)

Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study
por: Asbell, Penny A., et al.
Publicado: (2018)

Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018
por: Asbell, Penny A., et al.
Publicado: (2020)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
por: Haas, Wolfgang, et al.
Publicado: (2010)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%
por: DeCory, Heleen H., et al.
Publicado: (2020)

Antibiotic Resistance Rates by Geographic Region Among Ocular Pathogens Collected During the ARMOR Surveillance Study
por: Asbell, Penny A., et al.
Publicado: (2018)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2015)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
por: Mah, Francis S., et al.
Publicado: (2016)

Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
por: dos Santos, Giselly Almeida, et al.
Publicado: (2020)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
por: Torkildsen, Gail, et al.
Publicado: (2010)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
por: Haas, Wolfgang, et al.
Publicado: (2013)

Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009–2016)
por: Thomas, Randall K, et al.
Publicado: (2019)

In Vitro Antibiotic Resistance among Bacteria from the Cornea in the Antibiotic Resistance Monitoring in Ocular MicRoorganisms Surveillance Study
por: Thomas, Randall K., et al.
Publicado: (2021)

A Systematic Review of Multi-decade Antibiotic Resistance Data for Ocular Bacterial Pathogens in the United States
por: Bispo, Paulo J. M., et al.
Publicado: (2022)

Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation
por: de Jesus, José Izo Santana da Silva, et al.
Publicado: (2022)

Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
por: Schechter, Barry, et al.
Publicado: (2022)

Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach
por: Al Hagbani, Turki, et al.
Publicado: (2023)

Speciation and Antibiotic Susceptibilities of Coagulase Negative Staphylococci Isolated from Ocular Infections
por: Romanowski, John E., et al.
Publicado: (2021)

Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies
por: Schechter, Barry A
Publicado: (2019)

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial
por: Weyne, Jonathan, et al.
Publicado: (2020)

Association of Ocular Surface Immune Cells With Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study
por: Kuklinski, Eric J., et al.
Publicado: (2023)

The Role of SKQ1 (Visomitin) in Inflammation and Wound Healing of the Ocular Surface
por: Wei, Yi, et al.
Publicado: (2018)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Comstock, Timothy L, et al.
Publicado: (2010)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
por: Khimdas, S., et al.
Publicado: (2011)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease
por: Vittitow, Jason, et al.
Publicado: (2023)

The Effect of Topical Anesthetics on 16S Ribosomal Ribonucleic Acid Amplicon Sequencing Results in Ocular Surface Microbiome Research
por: Delbeke, Heleen, et al.
Publicado: (2022)

Development and Validation of Different Ultraviolet-Spectrophotometric Methods for the Estimation of Besifloxacin in Different Simulated Body Fluids
por: Singh, C. L., et al.
Publicado: (2015)

Antibiotic resistance genes & susceptibility patterns in staphylococci
por: Duran, Nizami, et al.
Publicado: (2012)

Ancient permafrost staphylococci carry antibiotic resistance genes
por: Kashuba, Elena, et al.
Publicado: (2017)

Antibiotic Resistance and Pathogenomics of Staphylococci Circulating in Novosibirsk, Russia
por: Bardasheva, Alevtina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g7uc87vl8cke8t2uahbs78v0bk